2019 Annual Meeting | S33 - Neuro-rehabilitation: Brain and Neuromuscular Recovery
Program Materials Program Evaluations
| 01:00 PM - 01:11 PM EDT | Abstract |
001 - Improvements in Spatial Bias and Functional Outcomes in Chronic Hemispatial Neglect: Results of a Multi-Site Phase II Efficacy Trial of a Novel Computerized Attention Training Program.
Tom Van Vleet |
| 01:11 PM - 01:22 PM EDT | Abstract |
002 - Preserved Brain Functional Plasticity After Upper Limb Task-Oriented Rehabilitation in Progressive Multiple Sclerosis
Giacomo Boffa |
| 01:22 PM - 01:33 PM EDT | Abstract |
003 - Clinically meaningful change on the 100 meter timed test in neuromuscular diseases
Lindsay N. Alfano, PT |
| 01:33 PM - 01:44 PM EDT | Abstract |
004 - Transcranial Direct Current Stimulation (tDCS) Induces Acute Changes in Brain Metabolism
Claire Sunha Choi, MD |
| 01:45 PM - 02:00 PM EDT | Q&A |
Q&A Panel with Authors
|
| Svetlana Pundik, MD | No disclosure on file |
| Steven C. Cramer, MD, FAAN | Dr. Cramer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Constant Therapeutics, BrainQ, Myomo, MicroTransponder, Panaxium, Beren Therapeutics, Medtronic, Stream Biomedical, NeuroTrauma Sciences, and TRCare. . Dr. Cramer has stock in Constant Therapeutics, Panaxium, and TRCare. The institution of Dr. Cramer has received research support from NIH; PCORI; Veterans Administration. |
| No disclosure on file | |
| Megan A. Waldrop, MD | Dr. Waldrop has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sarepta Therapeutics. Dr. Waldrop has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis Gene Therapies. |
| Louise R. Rodino-Klapac | Ms. Rodino-Klapac has received personal compensation for serving as an employee of Sarepta Therapeutics, Inc.. Ms. Rodino-Klapac has received stock or an ownership interest from Sarepta Therapeutics. Ms. Rodino-Klapac has received intellectual property interests from a discovery or technology relating to health care. |
| Giampaolo Brichetto, MD, PhD | Giampaolo Brichetto, MD, PhD has received personal compensation for serving as an employee of Italian MS Society. |
| Kevin M. Flanigan, MD, FAAN | Dr. Flanigan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apic Bio. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AavantiBio. Dr. Flanigan has stock in 4D Molecular Therapeutics. The institution of Dr. Flanigan has received research support from Abeona Therapeutics. The institution of Dr. Flanigan has received research support from Sarepta Therapeutics. The institution of Dr. Flanigan has received research support from Astellas Therapeutics. Dr. Flanigan has received intellectual property interests from a discovery or technology relating to health care. |
| Michael Shaw | Mr. Shaw has nothing to disclose. |
| Claire Sunha Choi, MD | Ms. Choi has nothing to disclose. |
| Tom Van Vleet | No disclosure on file |
| Natalie F. Miller, PT | Dr. Miller has received personal compensation for serving as an employee of ATOM International. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Casimir. |
| Maurizio Corbetta, MD | Dr. Corbetta has nothing to disclose. |
| Natalie Pawlak | No disclosure on file |
| Chang-Yong Tsao, MD, FAAN | No disclosure on file |
| Lauren B. Krupp, MD, FAAN | Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EBIX. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman LaRoche. Dr. krupp has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for MMMK. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Patrick, Dolan, and Kaufman. Dr. krupp has received intellectual property interests from a discovery or technology relating to health care. |
| Jerry R. Mendell, MD, FAAN | Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta Therapeutics . The institution of Dr. Mendell has received research support from Sarepta. |
| Leigh E. Charvet, PhD | Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Johnson & Johnson. Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Springer Healthcare. Dr. Charvet has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for YBrain. Dr. Charvet has stock in Johnson&Johnson. |
| Lindsay N. Alfano, PT | Ms. Alfano has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ATOM International, Ltd (Amicus Therapeutics, Catabasis, Genethon, Italfarmaco, NS Pharma, Pfizer, PTC Therapeutics). Ms. Alfano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta Therapeutics. The institution of Ms. Alfano has received research support from Novartis Gene Therapies. The institution of Ms. Alfano has received research support from Sarepta Therapeutics. The institution of Ms. Alfano has received research support from Audentes Therapeutics/Astellas Gene Therapies. Ms. Alfano has received intellectual property interests from a discovery or technology relating to health care. |
| Matilde Inglese, MD, PhD | Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI GENZYME. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOGEN. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS. Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for MERCK-SERONO. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MS Journal. |
| Linda P. Lowes, PT PhD | The institution of Ms. Lowes has received research support from Sarepta Therapeutics. |
| Giacomo Boffa | Mr. Boffa has nothing to disclose. |